'Criteria' aPL tests: Report of a Task Force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, Texas, April 2010

Lupus

Volumn 20, Issue 2, 2011, Pages 182-190

  Pierangeli, S S ^a   De Groot, P G ^b   Dlott, J ^c   Favaloro, E ^d   Harris, E N ^e   Lakos, G ^f   Ortel, T ^g   Meroni, P L ^h   Otomo, K ⁱ   Pengo, V ^j   Tincani, A ^k   Wong, R ^l   Roubey, R ^m  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^d WESTMEAD HOSPITAL   (Australia)

^e UNIVERSITY OF THE WEST INDIES   (Jamaica)

^f TheraTest Laboratories   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h ISTITUTO AUXOLOGICO ITALIANO   (Italy)

ⁱ HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j UNIVERSITY OF PADOVA   (Italy)

^k UNIVERSITY OF BRESCIA   (Italy)

^l ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

^m UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

more..

Author keywords

anti 2Glycoprotein I antibodies; Anticardiolipin antibodies; Antiphospholipid Syndrome; lupus anticoagulant; standardization

Indexed keywords

BETA2 GLYCOPROTEIN 1 ANTIBODY; CARDIOLIPIN ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; LUPUS ANTICOAGULANT; MONOCLONAL ANTIBODY; PHOSPHOLIPID ANTIBODY; POLYCLONAL ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; CLINICAL PROTOCOL; CONFERENCE PAPER; CONSENSUS DEVELOPMENT; DISEASE CLASSIFICATION; ENZYME LINKED IMMUNOSORBENT ASSAY; EVIDENCE BASED PRACTICE; HUMAN; LABORATORY TEST; PRACTICE GUIDELINE; PREGNANCY; PRIORITY JOURNAL; PROTHROMBIN TIME; RISK FACTOR; SCIENTIST; THROMBIN TIME; THROMBOSIS; UNITED STATES;

ADVISORY COMMITTEES; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; CONGRESSES AS TOPIC; DIAGNOSTIC TESTS, ROUTINE; FEMALE; GUIDELINES AS TOPIC; HUMANS; PREGNANCY; QUESTIONNAIRES; TEXAS;

EID: 79953299697     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203310395055     Document Type: Conference Paper

References (64)

1. Wilson WA, Gharavi AE, Koike T, et al. International consensus statement on preliminary classification for definite antiphospholipid syndrome. Arthritis Rheum 1999; 42: 1309-1311. (Pubitemid 30265586)
2. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
3. Favaloro EJ, Silvestrini R. Assessing the usefulness of anticardiolipin antibody assays: a cautious approach is suggested by high variation and limited consensus in multilaboratory testing. Am J Clin Pathol 2002; 118: 548-557. (Pubitemid 44698512)
4. Reber G, Schousboe I, Tincani A, et al. Inter-laboratory variability of anti-beta2-glycoprotein I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid Antibodies Standardization Group. Thromb Haemost 2002; 88: 66-73.
5. Harris EN, Gharavi AE, Patel S, Hughes GRC. Evaluation of the anticardiolipin antibody test: report of an international workshop held April 4 1986. Clin Exp Immunol 1987; 68: 215-222.
6. Harris EN. The second international anticardiolipin standardization workshop: the Kingston Anticardiolipin Antibody Study (KAPS) group. Am J Clin Pathol 1990; 101: 476-484. (Pubitemid 20316579)
7. Harris EN, Pierangeli S, Birch D. Anticardiolipin wet workshop report: Vth international symposium on antiphospholipid antibodies. Am J Clin Pathol 1994; 101: 616-624. (Pubitemid 24153820)
8. Pierangeli SS, Stewart M, Silva LK, Harris EN. Report of an anticardiolipin workshop during the VIIth International Symposium on antiphospholipid antibodies. J Rheumatol 1998; 25: 156-162.
9. Reber G, Arvieux J, Comby D, et al. Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. Thromb Haemost 1995; 73: 444-452.
10. Wong RCW, Wilson RJ, Pollock W, et al. Anticardiolipin antibody testing and reporting practices among laboratories participating in a large external Quality Assurance Program. Pathology 2004; 36: 174-181. (Pubitemid 38507880)
11. Tincani A, Allegri F, Sanmarco M, et al. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations - a cooperative project of the European Antiphospholipid Forum. Thromb Haemost 2001; 86: 575-583. (Pubitemid 32743269)
12. Harris EN, Pierangeli SS. Revisiting the anticardiolipin test and its standardization. Lupus 2002; 11: 269-275. (Pubitemid 34627428)
13. Kutteh WH, Franklin RD. Assessing the variation in antiphospholipid antibody (APA) assays: Comparison of results from 10 centers. Am J Obstet Gynecol 2004; 191: 440-448.
14. Wong RCW, Favaloro EJ, Pollock W, et al. A multi-centre evaluation of the intra-assay and inter-assay variation of commercial and in-house anti-cardiolipin antibody assays. Pathology 2004; 36: 182-192. (Pubitemid 38507881)
15. Wong RCW, Wilson RJ, Pollock W, Steele RH, Gillis D. Anticardiolipin antibody testing and reporting practices among laboratories participating in a large external Quality Assurance Program. Pathology 2004; 36: 174-181. (Pubitemid 38507880)
16. Goudemand J, Caron C, DeProst D, et al. Evaluation of the sensitivity and specificity of a standardized procedure using different reagents for the detection of lupus anticoagulants. The Working Group on Hemostasis of the Societe Francaise of Biologie Clinicque and for the Groupe d'Etudes surl Hemostase et la Thrombose. Thromb Haemost 1997; 77: 336-342. (Pubitemid 27084927)
17. Exner T, Triplett DA, Taberner DA, et al. Comparison of test methods for the lupus anticoagulant: international survey on lupus anticoagulants-1 (ISLA-1). Thromb Haemost 1990; 64: 478-484.
18. Hemostasis Committee of the Societe Francaise de Biologie Clinique. Laboratory heterogeneity of the lupus anticoagulant: a multicentre study using different clotting assays on a panel of 78 samples. Thromb Res 1992; 66: 349-364.
19. Working Group on Hemostasis of the Societe Francaise de Biologie Clinique. Comparison of a standardized procedure with current laboratory practices for the detection of lupus anticoagulant in France. Thromb Haemost 1993; 70: 781-786.
20. Jennings I, Kitchen S, Woods TA, et al. Potentially clinically important inaccuracies in testing for lupus anticoagulant: an analysis of results from three survey of the UK National External Quality Assessment Scheme (NEQAS) for Blood Coagulation. Thromb Haemost 1997; 77: 934-937. (Pubitemid 27239117)
21. Arnout J, Meijer P, Vermylen J. Lupus anticoagulant testing in Europe: an analysis of results from the first European Concerted Action on Thrombophilia (ECAT) survey using plasmas spiked with monoclonal antibodies against human β2glycopotein I. Thromb Haemost 1999; 81: 929-934. (Pubitemid 29312710)
22. Reber G, Tincani A, Sanmarco M, et al. Proposals for the measurement of anti-β2glycoprotein I antibodies. Standardization Group of the European Forum on Antiphospholipid Antibodies. J Thromb Haemost 2004; 2: 1860-1862. (Pubitemid 40192732)
23. Pierangeli SS, Harris EN. A quarter of a century in anticardiolipin antibody testing and attempted standardization has led us to here, which is? Semin Thromb Hemost 2008; 34: 313-328.
24. Reber G, Arvieux J, Comby E, et al. Multicenter evaluation of nine commercial kits for the quantitation of anticardiolipin antibodies. The Working Group on Methodologies in Haemostasis from the GEHT (Groupe d'Etudes sur l'Hemostase et la Thrombose). Thromb Haemost 1995; 73: 444-452.
25. Favaloro EJ, Silvestrini R. Assessing the usefulness of anticardiolipin antibody assays: a cautious approach is suggested by high variation and limited consensus in multilaboratory testing. Am J Clin Pathol 2002; 118: 548-557. (Pubitemid 44698512)
26. The Lupus Anticoagulant Working Party. Detection of lupus like anticoagulant: current laboratory practice in the United Kingdom. J Clin Pathol 1990; 43: 73-75.
27. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: an update. On behalf of the Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardization Committee of the ISTH. Thromb Haemost 1995; 74: 1185-1190.
28. Exner T, Triplett DA, Taberner D, Machin SJ. Guidelines for testing and revised criteria for lupus anticoagulants. SSC Subcommittee for the Standardization of Lupus Anticoagulants. Thromb Haemost 1991; 65: 320-322.
29. Pengo V, Tripodi A, Reber G, et al. Update of the guidelines for lupus anticoagulant detection. J Thromb Haemost 2009; 10: 1737-1740.
30. Lupus Anticoagulant Working Party on behalf of the BCSH Haemostasis and Thrombosis Task Force, Guidelines on Haemostasis and Thrombosis Task Force. Guidelines on testing for the lupus anticoagulant. J Clin Pathol 1991; 44: 885-889.
31. Favaloro EJ, Wong RC. Laboratory testing and identification of antiphospholipid antibodies and the antiphospholipid syndrome: A potpourri of problems, a compilation of possible solutions. Semin Thromb Hemost 2008; 34: 389-410.
32. Favaloro EJ, Silvestrini R, Mohammed A. Clinical utility of anticardiolipin antibody assays: high inter-laboratory variation and limited consensus by participants of external quality assurance programs signals a cautious approach. Pathology 1999; 31: 142-147. (Pubitemid 29264060)
33. Derksen W, Erkan D, Kaplan V, et al. Real world experience with antiphospholipid antibodies (APL): how stable are APL over time? Arthritis Rheum 2004; 50: S67.
34. Peaceman AH, Silver RK, MacGregor SN, Scool ML. Interlaboratory variation in antiphospholipid antibody testing. Am J Obstet Gynecol 1992; 144: 1780-1784.
35. Pierangeli SS, Gharavi MD, Harris EN. Testing for antiphospholipid antibodies: problems and solutions. Clin Obstet Gynecol 2001; 44: 48-57. (Pubitemid 32156080)
36. Reber Gm Schousboe I, Tincani A, et al. Inter-laboratory variability of anti β2glycoprotien I measurement. A collaborative study in the frame of the European Forum on Antiphospholipid antibodies Standardization Group. Thromb Haemost 2002; 88: 66-73.
37. Budd R, Harley E, Quarshie A, et al. A re-appraisal of the normal cut-off assignment for anticardiolipin IgM levels. J Thromb Haemost 2006; 10: 2210-2214. (Pubitemid 44400300)
38. Ruffatti A, Olivierri S, Tonello M, et al. Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost 2008; 1693-1696.
39. Trevisin M, Pollock W, Dimech W, et al. Antigen-specific ANCA ELISAs have different sensitivities for active and treated vasculitis and for nonvasculitic disease. Am J Clin Pathol 2008; 129: 42-53. (Pubitemid 352038593)
40. Reeves GE, Squance ML, Duggan AE, et al. Diagnostic accuracy of celiac serological tests: a prospective study. Eur J Gastroenterol Hepatol 2006; 18: 493-501. (Pubitemid 43832747)
41. Pierangeli SS, Harris EN. A protocol for determination of anticardiolipin antibodies by ELISA. Nat Protoc 2008; 3: 840-848. (Pubitemid 351639028)
42. Wong RCW, Gillis D, Adelstein S, et al. Consensus Guidelines on Anti-Cardiolipin Antibody Testing and Reporting. Pathology 2004; 36: 63-68. (Pubitemid 38223415)
43. Wong RC, Favaloro EJ. A consensus approach to the formulation of guidelines for laboratory testing and reporting of antiphospholipid antibody assays. Semin Thromb Hemost 2008; 34: 361-372.
44. Wong RC, Favaloro EJ, Adelstein S, et al. Consensus guidelines on anti-beta2 glycoprotein I testing and reporting. Pathology 2008; 40: 58-63. (Pubitemid 350172955)
45. Reber G, de Moerloose P. Anti-beta2 glycoprotein I antibodies- when and how should they be measured? Thromb Res 2004; 114: 527-531.
46. Tincani A, Allegri F, Sanmarco M, et al. Anticardiolipin antibody assay: a methodological analysis for a better consensus in routine determinations-a cooperative project of the European Antiphospholipid Forum. Thromb Haemost 2001; 86: 575-583. (Pubitemid 32743269)
47. Greaves M, Cohen H, Machin SJ, Mackie I. Guidelines on the investigation and management of the antiphospholipid syndrome. Br J Haematol 2000; 109: 704-715. (Pubitemid 30609746)
48. Wong RCW, Adelstein S, Gillis D, Favaloro EJ. Development of consensus guidelines for anticardiolipin antd lupus anticoagulant testing. Sem Thromb Haemost 2005; 31: 39-48. (Pubitemid 40262136)
49. Tincani A, Allegri F, Balestrieri G, et al. Minimal requirements for antiphospholipid antibodies ELISAs proposed by the European Forum on antiphospholipid antibodies. Thromb Res 2004; 114: 553-558. (Pubitemid 39422591)
50. Harris EN, Gharavi AE, Boey ML, et al. Anticardiolipin antibodies: detection by radioimmunoassay and association with thrombosis in systemic lupus erythematosus. Lancet 1983; 26: 1211-1214. (Pubitemid 14229783)
51. Matsuura E, Igarashi Y, Fujimoto M. Anticardiolipin antibodies directed not to cardiolipin but to a plasma protein cofactor. Lancet 1990; 336: 1547.
52. Ichikawa K, Tsutsumi A, Atsumi T, et al. A chimeric antibody with the human gamma1 constant region as a putative standard for assays to detect IgG beta2 glycoprotein I-dependent anticardiolipin and anti-beta2 glycoprotein I antibodies. Arthritis Rheum 1999; 42: 2461-2470. (Pubitemid 30333427)
53. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-310. (Pubitemid 16134762)
54. Recommendations for the preparation, characterization and establishment of international and other biological reference standards (revised 2004). World Health Organization WHO Technical Report Series, No. 932, 2006.
55. Lewis S, Keil LB, Binder WL, De Bari V. Standardized measurement of major immunoglobulin class (IgG, IgA and IgM) antibodies to β2glycoprotein 1 in patients with antiphospholipid syndrome. J Clin Lab Anal 1998; 12: 293-297. (Pubitemid 28462317)
56. Hlatky MA, Greenland P, Arnett DK, et al. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation 2009; 119: 2408-2416.
57. Pengo V, Biasiolo A, Pegoraro C, et al. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost 2005; 93: 1147-1152. (Pubitemid 40823521)
58. Ruffatti A, Olivieri S, Tonello M, et al. Influence of different IgG anticardiolipin antibody cut-off values on antiphospholipid syndrome classification. J Thromb Haemost 2008; 6: 1693-1696.
59. Urbanus RT, Siegerink B, Roest M, et al. Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study. Lancet Neurol 2009; 8: 998-1005.
60. Pengo V, Biasiolo A, Gresele P, et al. A comparison of lupus anticoagulant-positive patients with clinical picture of antiphospholipid syndrome and those without. Arterioscler Thromb Vasc Biol 2007; 27: 309-310.
61. de Groot PG, Lutters B, Derksen RH, et al. Lupus anticoagulants and the risk of a first episode of deep venous thrombosis. J Thromb Haemost 2005; 3: 1993-1997. (Pubitemid 43086056)
62. Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101: 1827-1832. (Pubitemid 36237580)
63. Pengo V, Ruffatti A, Legnani C, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost 2010; 8: 237-242.
64. Pengo V, Biasiolo A, Rampazzo P, Brocco T. dRVVT is more Sensitive than KCT or TTI for Detecting Lupus Anticoagulant Activity of Anti-b2-glycoprotein I Autoantibodies. Thromb Haemost 1999; 81: 256-258. (Pubitemid 29078313)